RUNX3 and bronchopulmonary dysplasia: Treatments with JMJD3 and DZNep effectively reversed RUNX3’s hyperoxia-induced downregulation, suggesting potential therapeutic strategies to alleviate BPD by targeting Runx3’s epigenetic regulation and related pathways (19, 50).